medication consists of a combination of two monoclonal antibodiesadministered through a subcutaneous injection which is indicated for cases of breast cancer HER2 positivea particularly aggressive form of the disease that It affects about 20% of patients.

Faster administration

The treatment injected into the thigh over 8 to 5 minutes for loading doses (first dose) and maintenance doses, respectively. Its administration is up to 90% faster compared to the intravenous standard, which takes hours, which represents a very important improvement for the quality of life of women who suffer from the disease.

Analysis of a mammogram. CÓRDOBA

medication combines two monoclonal antibodies, pertuzumab – ‘Perjeta’- and trastuzumab -Herceptin’, in the same vial by subcutaneous injection for the treatment of early and metastatic HER2-positive breast cancer. This route is preferred by patients and healthcare providers, and can be associated with a reduction of healthcare coststhe experts pointed out during the presentation of the treatment on Tuesday.

Tested in more than a dozen centers

The approval of the drug is based on the results of the phase 3 FeDeriCa bioequivalence trial, which showed that this therapy, compared to the fourth one, was non-inferior, maintaining a similar safety profile and comparable tumor response rates, indicates the pharmaceutical company that has promoted this therapeutic novelty. Eleven Spanish hospitals have participated in the clinical studies that endorse the approval of the new treatment.

A group of women wear pink ribbons to raise awareness about breast cancer. MANUEL MURILLO

Incidence of breast cancer in Córdoba

In cordoba the number of new cases of breast cancer diagnosed each year is around 500, according to the data provided by the Reina Sofía hospital, although in recent years there has been a downward trend in the average age of people who are diagnosed with the disease. If this cancer is diagnosed early, the Survival options reach between 85% and 90% of the total.

2023-06-02 04:32:02